1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Tens Of Thousands To Benefit From English Funding Nod For siRNA Cholesterol Drug Leqvio

The NHS Will Commission The Drug’s Rollout ‘With Immediate Effect’

 
• By Neena Brizmohun

A landmark population-level agreement between Novartis and the National Health Service for the gene silencing therapy Leqvio is now being implemented following the thumbs up from health technology assessment body NICE.

NICE says Leqvio is cost effective • Source: Alamy

As many as 300,000 people with high cholesterol or mixed dyslipidemia in England could be treated with Novartis’s gene silencing therapy Leqvio (inclisiran) over the next three years, after health technology assessment (HTA) body NICE backed making the cholesterol-lowering drug available on the National Health Service.

Leqvio, which is administered via twice-yearly injection in the primary care setting, is cost effective, NICE said in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

Safety Review Prompts EMA to Suspend Ixchiq Chikungunya Vaccine For Seniors

 
• By Neena Brizmohun

The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.